Ruxolitinib rechallenge in resistant or intolerant patients with myelofibrosis: Frequency, therapeutic effects, and impact on outcome.
Francesca PalandriMario TiribelliMassimo BrecciaDaniela BartolettiElena M ElliGiulia BenevoloBruno MartinoFrancesco CavazziniAlessia TieghiAlessandra IurloElisabetta AbruzzeseNovella PuglieseGianni BinottoGiovanni CaocciGiuseppe AuteriDaniele CattaneoMalgorzata M TrawinskaRossella StellaLuigi ScaffidiNicola PolverelliGiorgia MicucciElena MasselliMonica CrugnolaCostanza BosiFlorian H HeidelRoberto LatagliataFabrizio PaneAntonio CuneoMauro KramperaGianpietro SemenzatoRoberto M LemoliMichele CavoNicola VianelliMassimiliano BonifacioGiuseppe Alberto Maria PalumboPublished in: Cancer (2021)
Ruxolitinib rechallenge was mainly used in intolerant patients; there were clinical improvements and a possible survival advantage in many cases, but there was a substantial rate of permanent discontinuation. Ruxolitinib rechallenge should be balanced against newer therapeutic possibilities.